Novel endocrine therapy reduces the risk of breast cancer recurrence

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...
News-Medical.Net on MSN

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

Wistar scientists pinpoint a new approach to ovarian cancer treatment

Ovarian cancer tends to be resistant to hormone therapy, even when it should theoretically respond. Wistar Institute ...
The Manila Times

Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first ...

How fasting may boost breast cancer treatment: New research reveals a key hormone link

New research reveals that intermittent fasting can significantly enhance the effectiveness of oestrogen-blocking breast ...
Targeted Oncology

Giredestrant Improves IDFS vs SOC in ER+/HER2– Early Breast Cancer

Giredestrant significantly improved IDFS in ER-positive, HER2-negative early breast cancer, reducing recurrence or death risk by 30% compared to SOC endocrine therapy. Subgroup analyses showed ...
Precision Medicine Online

Roche's Giredestrant Topples Adjuvant Endocrine Therapy in Early Breast Cancer

The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...